(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
5 Affordable Travel Destinations To Visit In South America - 2More parents refusing this shot that prevents serious bleeding at birth
- 3Tremendous Spelunking: Cool Caverns All over the Planet
- 4The teen queen bee of 'Laguna Beach' is now a 'cringey' mom
- 5Mussolini's summer villa on Adriatic coast sold for €1.2 million
- High-Suggested Broilers For Your Homes
- Man threatens attack on German high-speed train, 12 lightly injured
- Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- The most effective method to Involve Handshakes for Compromise and Compromise
- Israel says it killed armed Hamas 'terrorists' in Gaza
- Palestinians reel under winter rains as Israel blocks Gaza shelter supplies
- Carrying on with a Sans plastic Way of life: Individual Examinations in Maintainability
- 'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- Artemis II astronauts are more than halfway to the moon as they seek to break Apollo 13's record
